A review of the use of somatostatin analogs in oncology

References

• WeckbeckerGRaulfFStolzBBrunsCSomatostatin analogs for diagnosis and treatment of cancerPharmacol Ther19936022452647912834
   PubMed Web of Science ®Google Scholar
• ZarogoulidisKEleftheriadouEKontakiotisTLong acting somatostatin analogues in combination to antineoplastic agents in the treatment of small cell lung cancer patientsLung Cancer2012761848822018594
   PubMed Web of Science ®Google Scholar
• PatelYCSomatostatin and its receptor familyFront Neuroendocrinol199920315719810433861
   PubMed Web of Science ®Google Scholar
• O’ByrneKJSchallyAVThomasACarneyDNStewardWPSomatostatin, its receptors and analogs, in lung cancerChemotherapy200147Suppl 27810811275704
   PubMed Web of Science ®Google Scholar
• Garcia de la TorreNWassJATurnerHEAntiangiogenic effects of somatostatin analoguesClin Endocrinol (Oxf)200257442544112354124
   PubMed Web of Science ®Google Scholar
• DasguptaPSomatostatin analogues: multiple roles in cellular proliferation, neoplasia, and angiogenesisPharmacol Ther20041021618515056499
   PubMed Web of Science ®Google Scholar
• VainasIGOctreotide in the management of hormone-refractory prostate cancerChemotherapy200147Suppl 210912611275705
   PubMed Web of Science ®Google Scholar
• ScarpignatoCPelosiniISomatostatin analogs for cancer treatment and diagnosis: an overviewChemotherapy200147Suppl 212911275699
   PubMed Web of Science ®Google Scholar
• LancranjanIBrunsCGrassPSandostatin LAR®: pharmacokinetics, pharmacodynamics, efficacy, and tolerability in acromegalic patientsMetabolism199544Suppl 11826
   Web of Science ®Google Scholar
• PollakMThe potential role of somatostatin analogues in breast cancer treatmentYale J Biol Med1997705–65355399825480
   PubMed Web of Science ®Google Scholar
• WolteringEAWatsonJCAlperin-LeaRCSomatostatin analogs: angiogenesis inhibitors with novel mechanisms of actionInvest New Drugs199715177869195291
   PubMed Web of Science ®Google Scholar
• RubinJAjaniJSchirmerWOctreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndromeJ Clin Oncol199917260060610080605
   PubMed Web of Science ®Google Scholar
• LudlamWHAnthonyLSafety review: dose optimization of somatostatin analogs in patients with acromegaly and neuroendocrine tumorsAdv Ther2011281082584121964965
   PubMed Web of Science ®Google Scholar
• CozziRDallabonzanaDAttanasioRBarausseMOppizziGA comparison between octreotide-LAR and lanreotide-SR in the chronic treatment of acromegalyEur J Endocrinol1999141326727110474124
   PubMed Web of Science ®Google Scholar
• ChansonPBoerlinVAjzenbergCComparison of octreotide acetate LAR and lanreotide SR in patients with acromegalyClin Endocrinol (Oxf)200053557758611106918
   PubMed Web of Science ®Google Scholar
• MurrayRDMelmedSA critical analysis of clinically available somatostatin analog formulations for therapy of acromegalyJ Clin Endocrinol Metab20089382957296818477663
   PubMed Web of Science ®Google Scholar
• BoccardoFAmorosoDManagement of breast cancer: is there a role for somatostatin and its analogs?Chemotherapy200147Suppl 2627711275703
   PubMed Web of Science ®Google Scholar
• VenninPPeyratJPBonneterreJLouchezMMHarrisAGDemailleAEffect of the long-acting somatostatin analogue SMS 201-995 (Sandostatin) in advanced breast cancerAnticancer Res1989911531552539768
   PubMed Web of Science ®Google Scholar
• O’ByrneKJDobbsNPropperDJPhase II study of RC-160 (vapreotide), an octapeptide analogue of somatostatin, in the treatment of metastatic breast cancerBr J Cancer1999799–101413141810188884
   PubMed Web of Science ®Google Scholar
• StolfiRParisiAMNatoliCIacobelliSAdvanced breast cancer: response to somatostatinAnticancer Res19901012032041970716
   PubMed Web of Science ®Google Scholar
• AndersonEFergusonJEMortenHShaletSMRobinsonELHowellASerum immunoreactive and bioactive lactogenic hormones in advanced breast cancer patients treated with bromocriptine and octreotideEur J Cancer199329A22092178422285
   PubMed Web of Science ®Google Scholar
• CanobbioLCannataDMigliettaLBoccardoFSomatuline (BIM 23014) and tamoxifen treatment of postmenopausal breast cancer patients: clinical activity and effect on insulin-like growth factor-I (IGF-I) levelsAnticancer Res1995156B268726908669848
   PubMed Web of Science ®Google Scholar
• Di LeoAFerrariLBajettaEBiological and clinical evaluation of lanreotide (BIM 23014), a somatostatin analogue, in the treatment of advanced breast cancer. A pilot study by the ITMO group. Italian Trials in Medical OncologyBreast Cancer Res Treat19953432372447579488
   PubMed Web of Science ®Google Scholar
• IngleJNSumanVJKardinalCGA randomized trial of tamoxifen alone or combined with octreotide in the treatment of women with metastatic breast carcinomaCancer19998561284129210189133
   PubMed Web of Science ®Google Scholar
• BajettaEProcopioGFerrariLA randomized, multicenter prospective trial assessing long-acting release octreotide pamoate plus tamoxifen as a first line therapy for advanced breast carcinomaCancer200294229930411900215
   PubMed Web of Science ®Google Scholar
• BontenbalMFoekensJALambertsSWFeasibility, endocrine and anti-tumour effects of a triple endocrine therapy with tamoxifen, a somatostatin analogue and an prolactin lowering drug in post-menopausal metastatic breast cancer: a randomized study with long-term follow-upBr J Cancer19987711151229459155
   PubMed Web of Science ®Google Scholar
• MacaulayVMSmithIEEverardMJTealeJDReubiJCMillarJLExperimental and clinical studies with somatostatin analogue octreotide in small cell lung cancerBr J Cancer19916434514561654981
   PubMed Web of Science ®Google Scholar
• AnthonyLJohnsonDHandeKSomatostatin analogue Phase I trials in neuroendocrine neoplasmsActa Oncol19933222172237686764
   PubMed Web of Science ®Google Scholar
• van HoekMHoflandLJde RijkeYBEffects of somatostatin analogs on a growth hormone-releasing hormone secreting bronchial carcinoid, in vivo and in vitro studiesJ Clin Endocrinol Metab200994242843319017754
   PubMed Web of Science ®Google Scholar
• Fainstein DayPFrohmanLGarcia RivelloHEctopic growth hormone-releasing hormone secretion by a metastatic bronchial carcinoid tumor: a case with a non hypophysial intracranial tumor that shrank during long acting octreotide treatmentPituitary200710331131917373589
   PubMed Web of Science ®Google Scholar
• ZatelliMCMaffeiPPiccinDSomatostatin analogs in vitro effects in a growth hormone-releasing hormone-secreting bronchial carcinoidJ Clin Endocrinol Metab20059042104210915671091
   PubMed Web of Science ®Google Scholar
• BearzALleshiAPerinTSmall cell lung cancer in an elderly patient: efficacy of somatostatin analog treatment, a case reportOnkologie201134311712021358216
   PubMedGoogle Scholar
• ParmarHCharltonCDPhillipsRHTherapeutic response to somatostatin analogue, BIM 23014, in metastatic prostatic cancerClin Exp Metastasis19921013111346375
   PubMed Web of Science ®Google Scholar
• LogothetisCJHossanEASmithTLSMS 201-995 in the treatment of refractory prostatic carcinomaAnticancer Res1994146B273127347872709
   PubMed Web of Science ®Google Scholar
• VainasIPasaitouKGalaktidouGThe role of somatostatin analogues in complete antiandrogen treatment in patients with prostatic carcinomaJ Exp Clin Cancer Res19971611191269148872
   PubMed Web of Science ®Google Scholar
• KoutsilierisMMitsiadesCDimopoulosTIoannidisANtounisALambouTA combination therapy of dexamethasone and somatostatin analog reintroduces objective clinical responses to LHRH analog in androgen ablation-refractory prostate cancer patientsJ Clin Endocrinol Metab200186125729573611739429
   PubMed Web of Science ®Google Scholar
• DimopoulosMAKiamourisCGikaDCombination of LHRH analog with somatostatin analog and dexmethasone versus chemotherapy in hormone-refractory prostate cancer: a randomized Phase II studyUrology200463112012514751362
   PubMed Web of Science ®Google Scholar
• MitsiadesCSBogdanosJKaramanolakisDMilathianakisCDimopoulosTKoutsilierisMRandomized controlled clinical trial of a combination of somatostatin analog and dexamethasone plus zolendronate vs zolendronate in patients with androgen ablation-refractory prostate cancerAnticancer Res2006265B3693370017094387
   PubMed Web of Science ®Google Scholar
• MitsogiannisICSkolarikosADeliveliotisCSomatostatin analog lanreotide in the treatment of castration-resistant prostate cancer (CRPC)Expert Opin Pharmacother200910349350119191684
   PubMed Web of Science ®Google Scholar
• Gonzalez-BarcenaDSchallyAVVadillo-BuenfilMResponse of patients with advanced prostatic cancer to administration of somatostatin analogue RC-160 (vapreotide) at the time of relapseProstate200356318319112772187
   PubMed Web of Science ®Google Scholar
• CascinuSCatalanoVGiordaniPBaldelliAMAgostinelliRCatalanoGGastrointestinal cancer refractory to chemotherapy: a role for octreotide?Chemotherapy200447Suppl 212713311275706
   PubMed Web of Science ®Google Scholar
• KlijnJGHoffAMPlantingASTreatment of patients with metastatic pancreatic and gastrointestinal tumours with the somatostatin analogue Sandostatin: a Phase II study including endocrine effectsBr J Cancer19906246276301977468
   PubMed Web of Science ®Google Scholar
• FazenyBBaurMProhaskaMOctreotide combined with goserelin in the therapy of advanced pancreatic cancer – results of a pilot study and review of the literatureJ Cancer Res Clin Oncol1997123145528996540
   PubMed Web of Science ®Google Scholar
• FriessHBuchlerMBeglingerCLow-dose octreotide treatment is not effective in patients with advanced pancreatic cancerPancreas1993855405458302789
   PubMed Web of Science ®Google Scholar
• BurchPABlockMSchroederGPhase III evaluation of octreotide versus chemotherapy with 5-fluorouracil or 5-fluorouracil plus leucovorin in advanced exocrine pancreatic cancer: a North Central Cancer Treatment Group studyClin Cancer Res2000693486349210999733
   PubMed Web of Science ®Google Scholar
• SulkowskiUBuchlerMPederzoliPA Phase II study of high-dose octreotide in patients with unresectable pancreatic carcinomaEur J Cancer199935131805180810673995
   PubMed Web of Science ®Google Scholar
• CascinuSDel FerroECatalanoGA randomised trial of octreotide vs best supportive care only in advanced gastrointestinal cancer patients refractory to chemotherapyBr J Cancer1995711971017819058
   PubMed Web of Science ®Google Scholar
• IftikharSYWatsonSAMorrisDLThe effect of long acting somatostatin analogue SMS 201.995 therapy on tumour kinetic measurements and serum tumour marker concentrations in primary rectal cancerBr J Cancer19916369719742069853
   PubMed Web of Science ®Google Scholar
• KouroumalisEAOctreotide for cancer of the liver and biliary treeChemotherapy200147Suppl 215016111275708
   PubMed Web of Science ®Google Scholar
• BeckerGAllgaierHPOlschewskiMZahringerABlumHEHECTOR Study GroupLong-acting octreotide versus placebo for treatment of advanced HCC: a randomized controlled double-blind studyHepatology200745191517187405
   PubMed Web of Science ®Google Scholar
• JiXQRuanXJChenHChenGLiSYYuBSomatostatin analogues in advanced hepatocellular carcinoma: an updated systematic review and meta-analysis of randomized controlled trialsMed Sci Monit2011178RA169RA17621804474
   PubMed Web of Science ®Google Scholar
• ZhaoBZhaoHZhaoNZhuXGCholangiocarcinoma cells express somatostatin receptor subtype 2 and respond to octreotide treatmentJ Hepatobiliary Pancreat Surg20029449750212483273
   PubMedGoogle Scholar
• GaalJde KrijgerRRNeuroendocrine tumors and tumor syndromes in childhoodPediatr Dev Pathol201013642744119708762
   PubMed Web of Science ®Google Scholar
• DishopMKKuruvillaSPrimary and metastatic lung tumors in the pediatric population: a review and 25-year experience at a large children’s hospitalArch Pathol Lab Med200813271079110318605764
   PubMed Web of Science ®Google Scholar
• Al-HussainiAButznerDTherapeutic applications of octreotide in pediatric patientsSaudi J Gastroenterol2012182879422421712
   PubMed Web of Science ®Google Scholar
• HeikenenJBPohlJFWerlinSLBucuvalasJCOctreotide in pediatric patientsJ Pediatr Gastroenterol Nutr200235560060912454572
   PubMed Web of Science ®Google Scholar
• KerteszGPHauserPVargaPDabasiGSchulerDGaramiMAdvanced pediatric inoperable thymus carcinoma (type C thymoma): case report on a novel therapeutic approachJ Pediatr Hematol Oncol2007291177477517984697
   PubMed Web of Science ®Google Scholar
• ManskyPJLiewehrDJSteinbergSMTreatment of metastatic osteosarcoma with the somatostatin analog OncoLar: significant reduction of insulin-like growth factor-1 serum levelsJ Pediatr Hematol Oncol200224644044612218590
   PubMed Web of Science ®Google Scholar
• LeongWLPasiekaJLRegression of metastatic carcinoid tumors with octreotide therapy: two case reports and review of the literatureJ Surg Oncol200279318018711870669
   PubMed Web of Science ®Google Scholar
• WaldherrCPlessMMaeckeHRHaldemannAMueller-BrandJThe clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical Phase II studyAnn Oncol200112794194511521799
   PubMed Web of Science ®Google Scholar
• RicciSAntonuzzoAGalliLOctreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotideAnn Oncol20001191127113011061606
   PubMed Web of Science ®Google Scholar
• YalcinSOyanBBayraktarYCurrent medical treatment of pancreatic neuroendocrine tumorsHepatogastroenterology2007547327828417419276
   PubMedGoogle Scholar
• KwekkeboomDJBakkerWHKamBLTreatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radio-labelled somatostatin analogue [177Lu-DOTA(0),Tyr3]octreotateEur J Nucl Med Mol Imaging200330341742212634971
   PubMed Web of Science ®Google Scholar
• de HerderWWvan der LelyAJLambertsSWSomatostatin analogue treatment of neuroendocrine tumorsPostgrad Med J1996728494034088935599
   PubMed Web of Science ®Google Scholar
• YalcinSAdvances in the systemic treatment of pancreatic neuroendocrine tumorsCancer Treat Rev201137212713220705397
   PubMed Web of Science ®Google Scholar
• ModlinIMPavelMKiddMGustafssonBIReview article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumoursAliment Pharmacol Ther201031216918819845567
   PubMed Web of Science ®Google Scholar
• RuszniewskiPDucreuxMChayvialleJATreatment of the carcinoid syndrome with the long-acting somatostatin analogue lanreotide: a prospective study in 39 patientsGut19963922792838977344
   PubMed Web of Science ®Google Scholar
• TomasettiPMiglioriMCorinaldesiRGulloLTreatment of gastroenteropancreatic neuroendocrine tumors with octreotide LARAliment Pharmacol Ther200014555756010792118
   PubMed Web of Science ®Google Scholar
• StrosbergJKvolsLAntiproliferative effect of somatostatin analogs in gastroenteropancreatic neuroendocrine tumorsWorld Gastroenterol2010162429632970
   PubMed Web of Science ®Google Scholar
• WalterTBrixi-BenmansourHLombard-BohasCCadiotGNew treatment strategies in advanced neuroendocrine tumoursDig Liver Dis20124429510521983252
   PubMedGoogle Scholar
• WelinSVJansonETSundinAHigh-dose treatment with a long-acting somatostatin analogue in patients with advanced midgut carcinoid tumoursEur J Endocrinol2004151110711215248829
   PubMed Web of Science ®Google Scholar
• AhmedATurnerGKingBMidgut neuroendocrine tumours with liver metastases: results of the UKINETS studyEndocr Relat Cancer200916388589419458024
   PubMed Web of Science ®Google Scholar
• YaoJCPhanAHoffPMTargeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment Phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2bJ Clin Oncol20082681316132318323556
   PubMed Web of Science ®Google Scholar
• DuranIKortmanskyJSinghDA Phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomasBr J Cancer20069591148115417031397
   PubMed Web of Science ®Google Scholar
• KaltsasGAPapadogiasDMakrasPGrossmanABTreatment of advanced neuroendocrine tumours with radiolabelled somatostatin analoguesEndocr Relat Cancer200512468369916322317
   PubMed Web of Science ®Google Scholar
• Sowa-StaszczakAPachDKunikowskaJEfficacy and safety of 90Y-DOTATATE therapy in neuroendocrine tumoursEndokrynol Pol201162539240022069099
   PubMed Web of Science ®Google Scholar
• AnthonyLBWolteringEAEspenanGDCroninMDMaloneyTJMcCarthyKEIndium-111-pentetreotide prolongs survival in gastroenteropancreatic malignanciesSemin Nucl Med200232212313211965607
   PubMed Web of Science ®Google Scholar
• ImhofABrunnerPMarincekNResponse, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancersJ Clin Oncol201129172416242321555692
   PubMed Web of Science ®Google Scholar
• ManniABoucherAEDemersLMHarveyHALiptonASimmondsMABartholomewMEndocrine effects of combined somatostatin analog and bromocriptine therapy in women with advanced breast cancerBreast Cancer Res Treat1989142892982575406
   PubMed Web of Science ®Google Scholar
• RosenbergLBarkunANDenisMHPollakMLow-dose octreotide and tamoxifen in the treatment of adenocarcinoma of the pancreasCancer19957523287804972
   PubMed Web of Science ®Google Scholar